Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris 11:39:30 2024-06-21 am EDT 5-day change 1st Jan Change
87.62 EUR -0.56% Intraday chart for Sanofi +1.38% -2.38%
LockThis Alphavalue article, the European leader in independent research, is only available to subscribers .
Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!
Already a customer? Log In
Sanofi: new Director of Group Corporate Affairs CF
Sanofi Appoints Audrey Duval Derveloy as Executive Vice President, Global Head of Corporate Affairs and Member of its Executive Committee, Effective July 1, 2024 CI
Sanofi: new positive data in hemophilia CF
US FDA Accepts Sanofi's New Drug Application for Hemophilia Treatment Fitusiran MT
Sanofi to Present New Data from its Hemophilia Portfolio at the 32nd Congress of the International Society on Thrombosis and Haemostasis CI
Cybersecurity firm Semperis raises $125 mln from JP Morgan, Hercules Capital RE
France’s Sanofi Partners with South Africa’s Biovac for Polio Vaccine Initiative MT
Sanofi: partnership with Biovac against polio in Africa CF
CAC40: falls below 7,600 pts in absence of Wall Street CF
Jasper Therapeutics, Inc. Announces Board Changes CI
Belharra Therapeutics, Inc. Announces Strategic Collaboration with Sanofi to Advance Discovery of Novel Small Molecule Therapeutics for Immunological Diseases CI
US FDA approves Merck's pneumococcal vaccine for adults RE
Bank Stocks Help Nudge European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading MT
Sanofi: positive phase 1/2 data in leukemia CF
Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial CI
Transcript : Sanofi Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 02:00 PM
CAC40: declines below 7800 points, weighed down by banks CF
Sanofi, Regeneron Secure US FDA Nod for Kevzara’s Use in Polyarticular Juvenile Idiopathic Arthritis MT
Sanofi: US indication extension for Kevzara CF
Regeneron, Sanofi Gain FDA Approval for Kevzara to Treat Juvenile Idiopathic Arthritis MT
Regeneron, Sanofi Get Expanded FDA OK for Kevzara in Polyarticular Juvenile Idiopathic Arthritis DJ
GSK Starts Appeal Against US State Court Ruling on Zantac Lawsuit MT
Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Has Approves Kevzara® CI
GSK takes first steps to appeal Zantac ruling in Delaware AN
GSK: decisions in the Zantac (ranitidine) litigation CF
Chart Sanofi
More charts
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
87.62 EUR
Average target price
108.2 EUR
Spread / Average Target
+23.48%
Consensus
  1. Stock Market
  2. Equities
  3. SAN Stock
  4. News Sanofi
  5. Sanofi: Sanofi’s healthy Q1 performance hailed by markets